-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Promoting Minorities in Hematology (PMH) Oral Presentations: Room I (for in-person participants)

Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Diversity, Equity, and Inclusion (DEI)
Saturday, December 9, 2023: 6:30 PM-8:00 PM
Marina Ballroom D (Marriott Marquis San Diego Marina)
ASH invites all interested meeting attendees to this event, which will showcase training and research opportunities geared toward increasing the diversity scholars in the field of hematology. The highlight of the session will be scientific presentations from the ASH Minority Medical Student Award, the ASH Minority Resident Hematology Award, the ASH Minority Hematology Graduate Award, and the ASH Minority Hematology Fellowship Award program participants.

A special reception celebrating the 20th anniversary of the Minority Recruitment Initiative (MRI) will follow presentations.

Efficacy of Brentuximab Vedotin Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma with and without Pre-Transplant Exposure to Novel Agents

Ayo S Falade, MD, MBA

Mass General Brigham Salem Hospital, Salem, MA
Pre-Clinical Developmental Hematopoiesis Cross-Species Comparative Analysis with KMT2A-Rearranged Infant Acute Lymphoblastic Leukemic Populations

Bianca A Ulloa, PhD

Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY
Discovering Mechanisms of Noncovalent BTK Inhibitor Resistance in CLL

Carla Barrientos Risso

Ponce Health Sciences University, Ponce, Puerto Rico
The Immune Checkpoint Siglec-15 in Promoting Immune Dysregulation in Non-Hodgkin Lymphomas

Dailia B. Francis, MD, PhD

Aflac Cancer & Blood Disorders Center at Children's Healthcare of Atlanta, Atlanta, GA
Expansion of KSHV-Specific T Cells for the Treatment of KSHV-Associated Malignancy

Danielle Sohai

Children's National Hospital, Washington, DC
Molecular MRD in a Phase 1 Study of Maintenance Azacitidine/Venetoclax after RIC-Ven Allogeneic HSCT in High Risk Myeloid Malignancies

H. Moses Murdock, MD

Dana-Farber Cancer Institute, Boston, MA
GPATCH8 As a Modulator of Mutant SF3B1

K. Ashley Lyttle

Meharry Medical College, Nashville, TN
Exploring the Underlying Mechanisms of BST2 in Hematopoietic Stem Cell Activation

Marcus Alexander Florez, PhD

Baylor College of Medicine, Houston, TX
Novel Causal Inference Method Estimates Treatment Effects in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms

Maria J. Fernandez Turizo, MD

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Brookline, MA
Assessing Disease-Specific Alterations within the Bone Marrow Microenvironment in JAK2 Dependent Neoplasms

Omonike Oyelola

University of Connecticut School of Medicine, Farmington, CT
Phenotypic and Molecular Consequences of Noncoding TET2 Perturbations in the Human Hematopoietic System

Tre Artis

Harvard University, Cambridge, MA
See more of: Special-Interest Sessions
<< Previous Session | Next Session >>